Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valproate + haloperidol is a combination of two pharmaceutical drugs used together for the treatment of acute mania in bipolar I disorder, and has also been studied as adjunct therapy in schizophrenic psychoses. **Valproate** is primarily an anticonvulsant and mood stabilizer that increases central nervous system levels of gamma-aminobutyric acid (GABA), reducing neuronal excitability and stabilizing mood. **Haloperidol** is a typical antipsychotic that antagonizes dopamine D2 receptors, providing antimanic and antipsychotic effects. When used together, the combination can be effective for controlling manic symptoms in bipolar I disorder, though safety concerns (adverse events, extrapyramidal symptoms) require close monitoring. Clinical studies indicate the combination is effective but may lead to increased adverse effects, such as extrapyramidal symptoms and metabolic changes, compared to other antipsychotic combinations[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valproate + haloperidol.